For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
This week in health care policy: October 24-30, 2026
FDA and innovation FDA and CMS move on personalized gene therapies. The FDA released draft guidance that lets developers of…
Blog
Market-oriented reforms that can save Medicare $100 billion
Since 1970, Medicare spending has grown from 0.7 percent of GDP to 4.0 percent of GDP, and it is projected to grow even further.
Blog
This week in health care policy: October 16–23, 2026
Medical innovation FDA approves several innovative treatments. Last week, the FDA granted accelerated approval to GSK’s Jemperli for certain untreated…
Search Posts
Blog
British Health (Mis)Care: No Complaints Allowed
The British government has found the right strategy to cut down on complaints about the National Health Service–convince patients that nothing can be done. Then…
Newsletter
Voter Fraud, Health Care Reforms and Latin American Politics
Competing legal teams prepare to do battle over allegations of voter fraud. A new report contrasts the competing health care plans announced by the major…
Blog
The Wonders of Socialized Health Care, Number 8,977
Ameirca’s health care system is messed up. Agreed. It is a bizarre amalgam of public and private, with government spending and tax policy creating counterproductive…
Newsletter
Bailout Fallout, the New (Green) Deal and Scaring Parents with Toxic Arguments
The House and Senate agree on a $700 billion financial bailout bill. Environmentalists try to leverage the mortgage and Wall Street financial crisis to argue…
Citation
the presidential candidates’ views on the biotech industry
Citation